Display options
Cite
Li W, Xu XL, Zhang J, et al. Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice. Oncol Lett. 2012;4(6):1269-1273doi: 10.3892/ol.2012.929.
Li, W., Xu, X. L., Zhang, J., Cai, J. H., & Tang, Y. X. (2012). Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice. Oncology letters, 4(6), 1269-1273. https://doi.org/10.3892/ol.2012.929
Li, Wei, et al. "Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice." Oncology letters vol. 4,6 (2012): 1269-1273. doi: https://doi.org/10.3892/ol.2012.929
Li W, Xu XL, Zhang J, Cai JH, Tang YX. Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice. Oncol Lett. 2012 Dec;4(6):1269-1273. doi: 10.3892/ol.2012.929. Epub 2012 Sep 20. PMID: 23205124; PMCID: PMC3506753.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2012 Dec;4(6):1269-1273. doi: 10.3892/ol.2012.929. Epub 2012 Sep 20.

Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice.

Oncology letters

Wei Li, Xiao-Li Xu, Jun Zhang, Jia-Hui Cai, Yun-Xian Tang

Affiliations

  1. Department of Gynecology, Nanjing Medical University of Hangzhou Hospital, Hangzhou, Zhejiang 310006, P.R. China.

PMID: 23205124 PMCID: PMC3506753 DOI: 10.3892/ol.2012.929

Abstract

The present study was designed to investigate whether cyclooxygenase (COX) inhibitors (coxibs) could prolong survival time by attenuating the tumor growth of ovarian cancer xenograft-bearing mice. Tumor growth and survival time were observed and compared in mice which were treated with a COX-1 inhibitor (SC-560) and a COX-2 inhibitor (celecoxib) every other day for a 21 day period from the day of tumor formation. The trial lasted a total of 121 days. The combination therapy resulted in statistically significant inhibition of tumor size compared with the control group (P<0.05). Additionally, single treatment of SC-560 or celecoxib significantly prolonged the mean survival time of mice compared with the control group (P<0.05). We suggest that COX-1 and COX-2 inhibitors may improve survival and inhibit tumor growth, and that the tumor growth inhibition by coxibs may be the contributing factor for the prolonged survival time in mouse xenograft models.

References

  1. Nat Rev Cancer. 2001 Oct;1(1):11-21 - PubMed
  2. Endocrinology. 2001 Jul;142(7):3198-206 - PubMed
  3. Eur J Clin Invest. 2008 Jan;38(1):61-6 - PubMed
  4. Endocrine. 2008 Jun;33(3):235-44 - PubMed
  5. Cancer Res. 2003 Feb 1;63(3):586-92 - PubMed
  6. Int J Cancer. 2008 Mar 15;122(6):1384-90 - PubMed
  7. Eur J Obstet Gynecol Reprod Biol. 2010 Jan;148(1):62-6 - PubMed
  8. N Engl J Med. 2000 Jun 29;342(26):1946-52 - PubMed
  9. Vet Comp Oncol. 2004 Mar;2(1):13-23 - PubMed
  10. Clin Cancer Res. 2004 Jul 15;10(14):4670-9 - PubMed
  11. Cancer Res. 1998 Jan 15;58(2):362-6 - PubMed
  12. Clin Cancer Res. 2005 Feb 15;11(4):1618-28 - PubMed
  13. Cancer Res. 2005 May 1;65(9):3735-44 - PubMed
  14. BMC Cancer. 2010 Nov 15;10:626 - PubMed
  15. Int J Cancer. 2004 Apr 20;109(4):576-80 - PubMed
  16. Clin Cancer Res. 2004 Jan 15;10(2):538-45 - PubMed
  17. Pathol Oncol Res. 2007;13(4):365-9 - PubMed
  18. Gynecol Oncol. 2008 Sep;110(3):418-24 - PubMed
  19. Cancer Res. 2000 Mar 1;60(5):1306-11 - PubMed
  20. Cancer. 2000 Dec 15;89(12):2637-45 - PubMed
  21. Am J Pathol. 2002 Mar;160(3):893-903 - PubMed
  22. J Biol Chem. 1996 Dec 27;271(52):33157-60 - PubMed
  23. Cancer Res. 2000 Nov 1;60(21):6045-51 - PubMed
  24. Int J Mol Sci. 2011 Jan 18;12(1):668-81 - PubMed
  25. Cancer. 2007 Feb 1;109(3):588-97 - PubMed
  26. J Thorac Oncol. 2011 Jun;6(6):1121-7 - PubMed
  27. Int J Mol Sci. 2010 Oct 19;11(10):3999-4013 - PubMed

Publication Types